Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5605428 | International Journal of Cardiology | 2017 | 31 Pages |
Abstract
Here we summarize some of the recent advances in the area of RAAS-modulators, including novel renin inhibitors, mineralcorticoid receptor antagonists and novel AT1 and AT2-receptor modulators. In addition, the pharmacology of a new class of compounds which display both AT1-receptor blocking properties combined with inhibition of neprilysin, the vasopeptidase enzyme degradating natriuretic peptide (ARNi), will be reviewed, alongside with their impact in the pathophysiology of chronic HF.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Vincenzo Mollace, Micaela Gliozzi, Annalisa Capuano, Francesco Rossi,